Skip to content

Trevi Therapeutics, Inc. TRVI Offering Costs Included In Accrued Expenses

Offering Costs Included In Accrued Expenses at other companies

Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$106K
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$0-100%
Arteris, Inc. logo
Arteris, Inc.AIP
$296K
Immunome logo
ImmunomeIMNM
$0-100%
NTS
Netskope, Inc. Class A Common StockNTSK
$0-100%
Septerna, Inc. logo
Septerna, Inc.SEPN
$0-100%

Other financials

Income statement

See full
Operating income-$14.9M-30.0%
Net income-$13.2M-27.6%
EPS (diluted)-$0.090.0%

Balance sheet

See full
Cash & equivalents$19.4M+0.2%
Total debt$682.0K-28.7%
Total equity$172.1M+73.1%
Total assets$179.6M+67.8%

Cash flow

See full
Operating cash flow-$16.7M-23.8%
CapEx$102.0K
Free cash flow-$16.8M

Valuation

See full
Market cap$2.47B+152%
Enterprise value$2.45B+157%

Returns & leverage

See full
Return on equity-33.6%-9.4pp
Debt / equity0.0×
Current ratio24.8×+9.4×

Where this comes from

Reported directly by Trevi Therapeutics, Inc. in its filing.

Tagged under the XBRL concept trvi:OfferingCostsIncludedInAccruedExpenses.

The official record: Trevi Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Trevi Therapeutics, Inc.'s offering costs included in accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Trevi Therapeutics, Inc.'s offering costs included in accrued expenses?
Trevi Therapeutics, Inc. (TRVI) reported offering costs included in accrued expenses of $58.25K in Q4 2024.
What is the long-term trend for Trevi Therapeutics, Inc.'s offering costs included in accrued expenses?
Over 2 years (2021 to 2024), Trevi Therapeutics, Inc.'s offering costs included in accrued expenses has grown at a 138.4% compound annual growth rate (CAGR), from $41K to $233K.
What does offering costs included in accrued expenses mean?
Captures the portion of costs related to equity or debt offerings that have been incurred but not yet paid in cash. These costs are recognized as liabilities on the balance sheet until settlement. Tracking this helps investors understand the total cost of capital-raising activities beyond immediate cash outflows.